Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2973 Target Snapshot

Rho-associated protein kinase 2 · SINGLE PROTEIN · Homo sapiens

8,425Compounds
744Assays
24Approved Drugs
8,929.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Rho-associated protein kinase 2 shows approved-linked disease relevance led by immune system disease. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt O75116. Start with immune system disease, then reuse UniProt O75116 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with immune system disease, then reuse UniProt O75116 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
immune system disease

Rho-associated protein kinase 2 shows approved-linked disease relevance led by immune system disease. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with immune system disease because it currently carries approved-linked support. Linked drugs include BELUMOSUDIL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Rho-associated protein kinase 2 as ChEMBL target CHEMBL2973, mapped to UniProt O75116. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Rho-associated protein kinase 2
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL2973
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
O75116
Rho-associated protein kinase 2
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Rho-associated protein kinase 2 is the right protein anchor across sources, using UniProt O75116 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why immune system disease is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelRho-associated protein kinase 2
UniProt AccessionO75116
Component TypeProtein
Sequence Length1388 aa

Rho-associated protein kinase 2

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Rho-associated protein kinase 2, mapped to UniProt O75116. Sequence length is 1388 aa.

Mapped IDO75116
Review nameRho-associated protein kinase 2
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Rho-associated protein kinase 2 shows approved-linked disease relevance led by immune system disease. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
immune system disease
1 linked drug · 1 direct · 1 efficacy
Linked drugBELUMOSUDIL
Late clinical Phase III
chronic graft versus host disease
1 linked drug · 1 direct · 1 efficacy
Linked drugBELUMOSUDIL
Clinical signal Phase II
diffuse scleroderma
1 linked drug · 1 direct · 1 efficacy
Linked drugBELUMOSUDIL
Clinical signal Phase II
graft versus host disease
1 linked drug · 1 direct · 1 efficacy
Linked drugBELUMOSUDIL
Clinical signal Phase II
idiopathic pulmonary fibrosis
1 linked drug · 1 direct · 1 efficacy
Linked drugBELUMOSUDIL
Clinical signal Phase II
psoriasis
1 linked drug · 1 direct · 1 efficacy
Linked drugBELUMOSUDIL
Source · ChEMBL drug mechanism + indication proxy
Review Cue

How to read disease relevance

Start review with immune system disease because it currently carries approved-linked support. Linked drugs include BELUMOSUDIL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseimmune system disease
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

24
Approved
13
Phase III
17
Phase II
17
Phase I
Assay Mix

Activity Type Distribution

IC507,288.0
KI1,245.0
EC508.0
KD388.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3666733 10.77 IC50 0.017 Preclinical
CHEMBL2023843 10.7 Kd 0.02 Preclinical
CHEMBL525385 10.68 Kd 0.021 Preclinical
CHEMBL3666753 10.64 IC50 0.023 Preclinical
CHEMBL3666735 10.44 IC50 0.036 Preclinical
CHEMBL3666738 10.31 IC50 0.049 Preclinical
CHEMBL5864025 10.0 IC50 0.1 Preclinical
CHEMBL3680709 9.8 IC50 0.16 Preclinical
CHEMBL3680738 9.77 IC50 0.17 Preclinical
CHEMBL3578252 9.74 IC50 0.18 Preclinical
Distribution

pChEMBL Value Distribution

304
5.0
628
5.5
776
6.0
1046
6.5
1145
7.0
1044
7.5
788
8.0
482
8.5
274
9.0
52
9.5
pChEMBL
Approved Drugs

Approved Drugs

MOMELOTINIB
CHEMBL1078178
Approved 2023
CAPIVASERTIB
CHEMBL2325741
Approved 2023
BELUMOSUDIL
CHEMBL2005186
Approved 2021
UPADACITINIB
CHEMBL3622821
Approved 2019
BARICITINIB
CHEMBL2105759
Approved 2017
NETARSUDIL
CHEMBL4594250
Approved 2017
PALBOCICLIB
CHEMBL189963
Approved 2015
TOFACITINIB CITRATE
CHEMBL2103743
Approved 2012
TOFACITINIB
CHEMBL221959
Approved 2012
BOSUTINIB
CHEMBL288441
Approved 2012
RUXOLITINIB
CHEMBL1789941
Approved 2011
VANDETANIB
CHEMBL24828
Approved 2011
SUNITINIB
CHEMBL535
Approved 2006
Assay Landscape

Assay Landscape

744
Total Assays
5,179
Tested Compounds
3
Assay Types
Binding — 741 assays, 5,179 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 603 4,570 7.2
cell-based format 63 335 7.3
assay format 62 253 7.3
subcellular format 13 21 5.9
Functional — 2 assays, 424 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 424 6.7
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine